trending Market Intelligence /marketintelligence/en/news-insights/trending/VEZPH61u_qOKWHh7y36u3Q2 content esgSubNav
In This List

Nemaura Medical closes $2M units offering to fund glucose monitor study

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Nemaura Medical closes $2M units offering to fund glucose monitor study

Nemaura Medical Inc. closed its offering of 1,942,061 units for gross proceeds of about $2 million.

Each unit consisted of a common share and a five-year common share purchase warrant exercisable at $1.04 per share. The units were priced at $1.04 apiece.

The company plans to use the proceeds for a U.S. Food and Drug Administration clinical trial of its noninvasive glucose monitor sugarBEAT. Proceeds will also be used to launch the product in Europe and to develop a second generation of sugarBEAT.

Dawson James Securities Inc. acted as the sole placement agent for the offering.

Loughborough, U.K.-based Nemaura is a medical technology company that develops specialty medical devices.